Joint Annual Meeting ISMRM-ESMRMB 2014 10-16 May 2014 Milan, Italy

PET-MRI & Whole Body MRI
SKILL LEVEL: Intermediate to Advanced
ORGANIZERS: John P. Mugler, III, Ph.D., Ivan Pedrosa, M.D., Scott B. Reeder, M.D., Ph.D. & Shreyas S. Vasanawala, M.D., Ph.D.
Monday, 12 May 2014
This combined scientific/educational session focuses on cutting edge developments in MR-PET technology and emerging clinical applications. Didactic educational overviews on MR-PET technology and clinical applications will set the stage for cutting edge scientific talks submitted to the meeting by leading groups pushing the frontiers of this new and exciting technology.
This course is designed for clinicians and imaging scientists interested in cutting edge technology and emerging clinical applications or MR-PET.

As a result of attending this course, participants should be able to:

  • Formulate the current state of the art MR-PET technology available for clinical application;
  • Illustrate emerging clinical applications of MR-PET; and
  • Identify remaining technical and clinical challenges of MR-PET.


Moderators: Alexander R. Guimaraes, M.D., Ph.D. & Ullrich Kramer, M.D.

10:45   Technical Challenges & Opportunities of MR-PET: An Overview
 - permission withheldd
Harald H. Quick, Ph.D.
11:15   Clinical Experience in Body MR-PET - permission withheld Ullrich Kramer, M.D.
11:45 0036.   Hybrid PET/MRI for Evaluation of Nodal Disease in Lymphoma
Laura Heacock1, Joseph Weissbrot1, Roy Raad1, Naomi Campbell1, Kent Friedman1, Christian Geppert2, and Hersh Chandarana1
1Radiology, NYU Langone Medical Center, New York, NY, United States, 2Siemens Medical Solutions, New York, NY, United States

PET/CT is routinely performed in evaluation of disease burden in patients with Non Hodgkin Lymphoma (NHL). MRI with diffusion weighted imaging (DWI) has shown promise. In this study we compared the accuracy of morphologic MRI including DWI and PET/MR in detection of nodal disease with PET/CT as a reference. Our results suggest that PET/MR outperformed DWI for assessment of nodal disease and had sensitivity similar to PET/CT. Furthermore there was excellent correlation in SUVmax as measured with PET/MR and PET/CT. Thus PET/MR may be a viable option to PET/CT in evaluation of patients with lymphoma.

11:55 0037.   Preliminary Results of Metabolic-flow relationship in primary cervical cancer: correlation of combined PET/Dynamic contrast-enhanced MRI - permission withheld
Omer Aras1, Volkan Beylergil2, Mark Hinton3, Olga Kubassova3, and Oguz Akin4
1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Radiology, Memorial Sloan Kettering Cancer, NY, United States, 3Image Analysis, London, United Kingdom, 4Radiology, Memorial Sloan Kettering Cancer, New York, NY, United States

In this preliminary data from 18F-FDG-PET/DCE-MRI in cervical cancer are reported. 18F-FDG PET and DCE-MRI tumor measures of tumor metabolism and vascularity were not correlated in this study indicating a complex interaction between tumor enhancement characteristics and tumor metabolism. information on the tumor.

12:05 0038.   Whole body 18FDG-PET/MRI as compared with 18FDG-PET/CT in metastatic breast cancer
Amy Melsaether1, Akshat C. Pujara2, Kristine Pysarenko2, Roy A. Raad2, Fabio Ponzo2, Kent Friedman2, Hersh Chandarana2, Komal Jhaveri2, Eric Sigmund2, Sungheon Kim2, and Linda Moy2
1NYU, New York, New York, United States, 2NYU, New York, United States

In this prospective disease-specific study of 50 breast cancer patients, 18FDG-PET/MRI detected potentially treatment changing brain, liver and bone metastases not seen on PET/CT in 8 (16%) or patients and PET/CT occult in situ breast cancers in 5 (10%). Average 18FDG-PET/MRI radiation dose was 50% that of 18FDG-PET/CT.

12:15 0039.   Hybrid PET/MRI incorporating Dynamic 18F-FDG PET Imaging: Correlation with Biopsy Findings-Preliminary Observations
Andrew B Rosenkrantz1, Anne-Kristin Vahle1, Christian Geppert2, Christopher Glielmi2, Fabio Ponzo1, Kent P Friedman1, Samir S Taneja3, Yu-Shin Ding1, and Thomas Koesters1
1Center for Advanced Imaging Innovation and Research, Department of Radiology, NYU Langone Medical Center, New York, NY, United States, 2Siemens Healthcare, Erlangen, Germany, 3Urologic Oncology, NYU Langone Medical Center, New York, New York, United States

This pilot study of 12 prostate cancer patients explores associations between metrics obtained from PET/MRI incorporating dynamic 18F-FDG PET imaging and biopsy findings. DCE-MRI and dynamic PET were performed simultaneously following sequential injections of gadolinium-chelate and FDG. Dynamic PET data was reconstructed in 30-second bins for the first 5 minutes, followed by 5-minute bins for the remainder of a 30-minute acquisition. Peak and 30-minute FDG activity were determined from FDG time-activity-curves and compared among benign and low- and high-grade tumors. The peak FDG activity showed the strongest association with biopsy results, supporting the value of dynamic PET imaging during PET/MRI.

12:25 0040.   PET/MRI and PET/CT in follow-up of head and neck cancer patients
Marcelo Queiroz1, Christian Meerwein2, Gerhard Huber2, Martin Hüllner1, Felix Kuhn1, Spyros Kollias3, Gustav von Schulthess1, and Patrick Veit-Haibach1
1Medical Imaging, Zurich University Hospital, Zurich, Zurich, Switzerland, 2Otorhinolaryngology, Zurich University Hospital, Zurich, Switzerland,3Neuroradiology, Zurich University Hospital, Zurich, Switzerland

Our abstract compares the novel PET/MRI and the well established PET/CT in the follow-up of head and neck patients. PET/MRI emerges as a potential imaging modality that joins the functional ability of PET and the high-soft tissue contrast provided by MRI, but it might be shown the real advantages of this method.

12:35 0041.   In vivo characterization of inflammation by combined [11C]-PBR28 PET imaging and 7 Tesla MRI in multiple sclerosis - permission withheld
Costanza Gianni'1, Audrey Fan1, Sindhuja Tirumalai Govindarajan1, Marco Loggia1, Nicole Zurcher Wimmer1, Ciprian Catana1, Jacob Hooker1, Emanuele Tinelli2, Celine Louapre1, Thomas A Anderson3, R.P. Kinkel4, and Caterina Mainero1
1Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States, 2Neurology and Psychiatry, Sapienza, University of Rome, Rome, Italy, 3Massachusetts General Hospital, Boston, MA, United States, 4Beth Israel Deaconess Medical Center, Boston, MA, United States

Inflammation through activation of macrophages and microglia is a prominent feature in multiple sclerosis. However, the relationship between activated microglia / macrophages and structural damage in the brain relies mainly on neuropathological studies. Here, we combined [11C]PBR28 imaging of activated microglia on a high resolution, simultaneous human MR-PET system with 7 Tesla in patients with secondary progressive multiple sclerosis. We observed diffuse microglia and macrophage activation across the cortex and WM, which topographically overlapped with visible lesions on 7 T T2* images in some regions.
12:45     Adjournment